SRNE Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 15:54):

Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases...

Stats
Today's Volume	54 423.00
Average Volume	329 980
Market Cap	7.51M
EPS	$-0.175 ( 2023-06-29 )
Next earnings date	( $0 ) 2024-05-24
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0100
ATR14	$0.00100 (7.30%)

Insider Trading

Date	Person	Action	Amount	type
2023-03-17	Ji Henry	Buy	19 500	Common Stock
2023-03-17	Ji Henry	Sell	195	Put Option (obligation to buy)
2021-12-31	Janda Kim	Buy	0
2022-12-21	Ji Henry	Buy	300	Common Stock
2022-12-02	Ji Henry	Buy	200	Common Stock

INSIDER POWER
99.97
Last 96 transactions
Buy: 40 331 586 \| Sell: 980 682

Sorrento Therapeutics Inc Correlation

10 Most Positive Correlations
INCR	0.893
RPRX	0.888
GCBC	0.882
HYRE	0.875
IXHL	0.875
SPFI	0.863
MICS	0.862
KTTA	0.861
WATT	0.857
BWB	0.853

10 Most Negative Correlations
ESCA	-0.906
BREZ	-0.903
BRLI	-0.886
OPRA	-0.882
ITAQU	-0.882
AUPH	-0.882
GRIL	-0.877
PBBK	-0.874
ESPO	-0.873
CNGL	-0.873

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Sorrento Therapeutics Inc Financials

Annual	2022
Revenue:	$62.84M
Gross Profit:	$29.39M (46.77 %)
EPS:	$-1.330

FY	2022
Revenue:	$62.84M
Gross Profit:	$29.39M (46.77 %)
EPS:	$-1.330

FY	2021
Revenue:	$52.90M
Gross Profit:	$39.87M (75.37 %)
EPS:	$-1.450

FY	2020
Revenue:	$39.99M
Gross Profit:	$30.05M (75.14 %)
EPS:	$-1.300

Financial Reports:

No articles found.

Sorrento Therapeutics Inc

Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis knee pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; Celularity, Inc. for initiating Phase I/II clinical study, including up to 94 patients with COVID-19; Mount Sinai Health System to develop COVI-SHIELD, an antibody therapy targeting SARS-CoV-2 infection; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California.